PharmiWeb.com - Global Pharma News & Resources
26-May-2023

Hospital-Acquired Infection Control Market : Surging Demand to Propel Growth to USD 25 Billion by 2030

The global Hospital-acquired infection control industry generated $19.95 billion in 2020, and is expected to generate $25.00 billion by 2030, witnessing a CAGR of 4.6% from 2022 to 2030.

The hospital-acquired infection control market refers to the market for products, services, and measures aimed at preventing and controlling infections acquired within healthcare settings such as hospitals, clinics, and long-term care facilities. These infections, also known as healthcare-associated infections (HAIs) or nosocomial infections, can occur due to various factors such as contaminated surfaces, inadequate hand hygiene, improper sterilization of medical equipment, and the transmission of pathogens between patients and healthcare workers.

๐ƒ๐จ๐ฐ๐ง๐ฅ๐จ๐š๐ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ : https://www.alliedmarketresearch.com/request-sample/11359

Drivers, restraints, and opportunities

Increase in incidence of hospital-acquired infections, rise in likelihood of epidemic or pandemic outbreaks, and surge in chronic disease incidences drive the growth of the global hospital-acquired infection control market. However, fatal effects of chemical disinfectants hinder the market growth. On the other hand, high potential in emerging countries creates new opportunities in the coming years.

๐–๐ก๐š๐ญ ๐ข๐ฌ ๐ญ๐ก๐ž ๐ˆ๐ฆ๐ฉ๐š๐œ๐ญ ๐จ๐Ÿ ๐‚๐จ๐ฏ๐ข๐-๐Ÿ๐Ÿ— ๐๐š๐ง๐๐ž๐ฆ๐ข๐œ ๐จ๐ง ๐‡๐จ๐ฌ๐ฉ๐ข๐ญ๐š๐ฅ-๐€๐œ๐ช๐ฎ๐ข๐ซ๐ž๐ ๐ˆ๐ง๐Ÿ๐ž๐œ๐ญ๐ข๐จ๐ง ๐‚๐จ๐ง๐ญ๐ซ๐จ๐ฅ ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐†๐ฅ๐จ๐›๐š๐ฅ๐ฅ๐ฒ?

  • Manufacturers of hospital-acquired infection (HAI) control products have been expanding their production capacities for medical nonwovens such as gloves, masks, and gowns to cater to the increase in demand with an outbreak of the Covid-19 pandemic.
  • Increase in the number of Covid-19 cases and rise in need for safety of healthcare workers are projected to increase the demand for protective barrier products and disposable hospital supplies. This would present new avenues for manufacturers of HAI control products.
  • With rise in number of surgeries performed at hospitals and need for safety and prevention of cross-contamination in clinics, the demand for sterilization and cleaning and disinfection products would also rise.

๐๐ซ๐จ๐œ๐ฎ๐ซ๐ž ๐‚๐จ๐ฆ๐ฉ๐ฅ๐ž๐ญ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ (๐Ÿ๐ŸŽ๐ŸŽ ๐๐š๐ ๐ž๐ฌ ๐๐ƒ๐… ๐ฐ๐ข๐ญ๐ก ๐ˆ๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ, ๐‚๐ก๐š๐ซ๐ญ๐ฌ, ๐“๐š๐›๐ฅ๐ž๐ฌ, ๐š๐ง๐ ๐…๐ข๐ ๐ฎ๐ซ๐ž๐ฌ) @ https://www.alliedmarketresearch.com/checkout-final/223dd787c61ad72ca9820cd7dde968b6

The protective barriers segment to maintain its lead position during the forecast period

Based on product & service, the protective barriers segment held the largest share in 2020, accounting for more than three-fourths of the global hospital-acquired infection control market, and is estimated to maintain its lead position during the forecast period. This is due to surge in adoption of medical nonwovens such as surgical drapes, face masks, and gowns with increase in Covid-19 cases, rise in number of surgeries, and surge in public awareness toward personal hygiene. However, the sterilization segment is projected to witness the largest CAGR of 5.9% from 2022 to 2030, owing to rise in hospital-acquired infections (HAI), surge in outsourcing of sterilization services, re-introduction of ethylene oxide sterilization, and increase in the incidence of chronic diseases such as diabetes, cancer, and other autoimmune diseases.

๐๐ฎ๐ซ๐œ๐ก๐š๐ฌ๐ž ๐ˆ๐ง๐ช๐ฎ๐ข๐ซ๐ฒ: https://www.alliedmarketresearch.com/purchase-enquiry/11359

The hospitals and clinics segment to continue its leadership status throughout the forecast period

Based on end user, the hospitals and clinics segment accounted for the highest share in 2020, contributing to more than three-fourths of the global hospital-acquired infection control market, and is projected to continue its leadership status throughout the forecast period. Moreover, this segment is expected to portray the fastest CAGR of 4.8% from 2022 to 2030. This is attributed to increase in the geriatric population that is more susceptible to various chronic diseases, surge in volume of surgical procedures carried out in hospitals, and increase in number of hospitals & clinics worldwide. The report also analyzes the segments including ambulatory surgical centers and others.

North America to continue its dominant share by 2030

Based on region, North America contributed to the largest market share in terms of revenue in 2020, holding more than one-third of the global hospital-acquired infection control market, and is expected to continue its dominant share by 2030. This is due to increase in adoption of sterilization & disinfection products along with contract sterilization services and surge in need for hospital-acquired infection control measures to minimize the prevalence. However, Asia-Pacific is estimated to manifest the fastest CAGR of 5.4% during the forecast period, owing to rise in awareness related to personal hygiene, surge in the number of surgical procedures, availability of trained medical professionals, and favorable reimbursement policies in the healthcare system.

๐‡๐จ๐ฌ๐ฉ๐ข๐ญ๐š๐ฅ-๐€๐œ๐ช๐ฎ๐ข๐ซ๐ž๐ ๐ˆ๐ง๐Ÿ๐ž๐œ๐ญ๐ข๐จ๐ง ๐‚๐จ๐ง๐ญ๐ซ๐จ๐ฅ ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐Š๐ž๐ฒ ๐๐ฅ๐š๐ฒ๐ž๐ซ๐ฌ:

  • 3M Company
  • Belimed AG
  • Ecolab Inc.
  • Fortive (Advanced Sterilization Products)
  • Getinge AB
  • Matachana Group
  • Miele Group
  • MMM Group
  • Sotera Health LLC
  • Steris Plc. (Cantel Medical Corporation)

๐“๐ซ๐ž๐ง๐๐ข๐ง๐  ๐‘๐ž๐ฉ๐จ๐ซ๐ญ๐ฌ ๐ข๐ง ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐ˆ๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ:

Cell and gene supply chain services market Share: https://www.alliedmarketresearch.com/cell-and-gene-supply-chain-services-market-A08188

Rare Disease Genetic Testing Market Size: https://www.alliedmarketresearch.com/rare-disease-genetic-testing-market-A10305

๐‚๐จ๐ง๐ญ๐š๐œ๐ญ:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

๐€๐›๐จ๐ฎ๐ญ ๐”๐ฌ โ€“

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โ€œMarket Research Reportsโ€ and โ€œBusiness Intelligence Solutions.โ€ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Editor Details

  • Company:
    • The Wire Times
Last Updated: 26-May-2023